Stock Events

Stock Events

Ultragenyx Pharmaceutical 

$15.30
45
+$0.45+3.03% Friday 20:00
+$0.08+0.52%Friday 23:59After hours

Statistics

Day High
15.3
Day Low
15.24
52W High
39.89
52W Low
13.81
Volume
431,379
Avg. Volume
-
Mkt Cap
1.51B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-1.84
-1.52
-1.19
-0.87
Expected EPS
-0.869374
Actual EPS
N/A

Financials

-85.44%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
673MRevenue
-575MNet Income

Analyst Ratings

29.88Average Price Target
The highest estimate is 74.00.
From 17 ratings within the last 6 months. This is not an investment recommendation.
Buy
65%
Hold
35%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RARE. It's not an investment recommendation.
NVIDIA
12
NVDA
Apple
9
AAPL
Amazon
9
AMZN
D-Wave Quantum
9
QBTS

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Ultragenyx's focus on rare genetic disorders.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical competes directly with Ultragenyx in the rare disease space, particularly in developing enzyme replacement therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in developing treatments for rare diseases among other areas, making it a competitor.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk is a leading company in diabetes care but also ventures into treatments for rare blood disorders, competing with Ultragenyx.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, known for its work in antiviral drugs, also has a portfolio in other areas including rare diseases, making it a competitor.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a broad focus on biologics in various therapeutic areas, including rare diseases, competing with Ultragenyx in this niche.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a diversified portfolio that includes treatments for rare diseases, making it a competitor to Ultragenyx.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurological diseases, including some rare conditions, positioning it as a competitor in the rare disease market.

About

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Show more...
CEO
Emil D. Kakkis
Employees
1371
Country
United States
ISIN
US90400D1081
WKN
000A1XCY0

Listings

STU
DE
UP0.STU
SA
BR
R2AR34.SA
LSE
GB
0LIF.LSE
F
DE
UP0.F

0 Comments

Share your thoughts

FAQ

What is Ultragenyx Pharmaceutical stock price today?▼
The current price of RARE is $15.30 USD — it has increased by +3.03% in the past 24 hours. Watch Ultragenyx Pharmaceutical stock price performance more closely on the chart.
What is Ultragenyx Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Ultragenyx Pharmaceutical stocks are traded under the ticker RARE.
Is Ultragenyx Pharmaceutical stock price growing?▼
RARE stock has fallen by -40.26% compared to the previous week, the month change is a -38.63% fall, over the last year Ultragenyx Pharmaceutical has showed a -51.92% decrease.
What is Ultragenyx Pharmaceutical market cap?▼
Today Ultragenyx Pharmaceutical has the market capitalization of 1.51B
When is the next Ultragenyx Pharmaceutical earnings date?▼
Ultragenyx Pharmaceutical is going to release the next earnings report on November 04, 2026.
What were Ultragenyx Pharmaceutical earnings last quarter?▼
RARE earnings for the last quarter are -0.9 USD per share, whereas the estimation was -1.22 USD resulting in a +26.09% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ultragenyx Pharmaceutical revenue for the last year?▼
Ultragenyx Pharmaceutical revenue for the last year amounts to 673M USD.
What is Ultragenyx Pharmaceutical net income for the last year?▼
RARE net income for the last year is -575M USD.
How many employees does Ultragenyx Pharmaceutical have?▼
As of September 05, 2026, the company has 1,371 employees.
In which sector is Ultragenyx Pharmaceutical located?▼
Ultragenyx Pharmaceutical operates in the Health & Wellness sector.
When did Ultragenyx Pharmaceutical complete a stock split?▼
The last stock split for Ultragenyx Pharmaceutical was on August 12, 2003 with a ratio of 3:2.
Where is Ultragenyx Pharmaceutical headquartered?▼
Ultragenyx Pharmaceutical is headquartered in NOVATO, United States.